AIA Group Ltd Acquires New Position in United Therapeutics Co. (NASDAQ:UTHR)

AIA Group Ltd bought a new position in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 608 shares of the biotechnology company’s stock, valued at approximately $215,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. O Shaughnessy Asset Management LLC grew its position in shares of United Therapeutics by 6.2% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company’s stock worth $1,387,000 after acquiring an additional 228 shares during the last quarter. Allstate Corp acquired a new position in United Therapeutics during the 4th quarter valued at about $415,000. Orion Portfolio Solutions LLC grew its position in United Therapeutics by 22.4% in the 4th quarter. Orion Portfolio Solutions LLC now owns 4,021 shares of the biotechnology company’s stock worth $1,419,000 after purchasing an additional 735 shares during the last quarter. denkapparat Operations GmbH acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $394,000. Finally, Pictet Asset Management Holding SA raised its holdings in shares of United Therapeutics by 142.6% during the fourth quarter. Pictet Asset Management Holding SA now owns 118,091 shares of the biotechnology company’s stock valued at $41,667,000 after buying an additional 69,411 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent analyst reports. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $388.25.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $939,625.74. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock valued at $26,134,500 over the last quarter. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 0.5 %

Shares of United Therapeutics stock opened at $306.88 on Wednesday. United Therapeutics Co. has a 12-month low of $225.62 and a 12-month high of $417.82. The firm has a market capitalization of $13.78 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The stock’s fifty day moving average is $337.82 and its 200-day moving average is $355.39.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company earned $4.36 EPS. Analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.